[新聞] Alvogen宣佈向Lotus（美時）出售股份已刪文

看板Stock (股票)作者lfnet4 (康叔)時間2周前 (2025/09/24 04:13)推噓0(0推 0噓 0→)

留言0則, 0人參與討論串1/1

原文標題： Alvogen宣佈向Lotus出售股份，打造領先的國際專業仿製藥平台 ※請勿刪減原文標題原文連結： https://news.futunn.com/t/hk/post/62498179/InzbaUnj7e ※網址超過一行過長請用縮網址工具發布時間：2025/9/24 04：02 ※請以原文網頁/報紙之發布時間為準記者署名： ※原文無記載者得留空新澤西州莫里斯敦，2025年9月23日 /PRNewswire/ -- Alvogen Pharma US, Inc.（「Alvogen」），一家美國私有制製藥公司，今天宣佈其股東達成了一項最終協議，將其母公司出售給蓮花葯業股份有限公司（「蓮花」，TWSE：1795）。根據協議條款，Alvogen將成爲蓮花的控股子公司，需遵循慣例的交割條件。 The agreement builds upon the existing long-standing collaboration between Alvogen and Lotus including several highly successful co-developed product launches, and gives Lotus access to a U.S. platform including a dedicated salesforce, in-house manufacturing at Alvogen's Norwich, New York facility, and a complementary R&D pipeline. 該協議建立在Alvogen與Lotus之間長期合作的基礎上，包括多個成功共同開發的產品發佈，併爲Lotus提供了一個美國平台，包括專門的銷售團隊、位於Alvogen位於紐約諾里奇的工廠的內部生產，以及一個互補的研發管道。 "This acquisition represents a culmination of Alvogen's operational excellence and targeted portfolio aimed at sustainable growth. Joining Lotus positions Alvogen for its next stage of expansion into multiple segments. With Lotus' global partnerships and APAC distribution, we expect to extend the reach of our specialized generics and brands while maintaining our commitment to quality and reliable supply from our Norwich facility," said Lisa Graver, Chief Executive Officer, Alvogen. 「此次收購代表了Alvogen在運營卓越和可持續增長目標組合方面的巔峰成就。加入Lotus使Alvogen能夠進入下一個擴展階段，覆蓋多個領域。憑藉Lotus的全球合作伙伴關係和亞太地區的分銷，我們預計將擴大我們專業仿製藥和品牌的覆蓋範圍，同時保持我們對質量和來自諾里奇工廠的可靠供應的承諾，」Alvogen首席執行官Lisa Graver說道。 Robert Wessman, Chairman of Alvogen and Lotus, added: "We are excited to combine Alvogen with Lotus Pharmaceutical. This acquisition represents a natural evolution of our long-standing partnership and provides our specialty portfolio and dedicated team with a broader platform for growth and impact. Importantly, this deal is also a testament to Lotus' proven strategy — growing our presence in core areas in APAC and US, developing new opportunities through B2B and M&A, and bolstering our specialty pipeline. With this consistent vision, we will continue building a sustainable growth path and delivering value for patients and stakeholders globally." Alvogen和Lotus董事長羅伯特·韋斯曼補充說：「我們很高興將Alvogen與蓮花製藥合併。此次收購代表了我們長期合作關係的自然演變，爲我們的專業產品組合和專業團隊提供了更廣泛的增長和影響力平台。重要的是，這筆交易也證明了Lotus久經考驗的戰略——擴大我們在亞太和美國核心領域的影響力，通過B2B和併購開發新的機會，加強我們的專業渠道。本着這一始終如一的願景，我們將繼續建立可持續的增長道路，爲全球患者和利益相關者創造價值。」 Advisors 顧問 Jefferies LLC and Rothschild & Co acted as joint financial advisors to Alvogen on this transaction, and White & Case LLP acted as legal advisor. 傑富瑞公司和羅斯柴爾德公司在此交易中擔任了阿爾沃根的聯合財務顧問，懷特＆凱斯律師事務所擔任法律顧問。 About Alvogen 關於Alvogen Alvogen is a privately-owned company focused on developing, in-licensing, manufacturing and marketing pharmaceutical products. Alvogen is growing its portfolio of complex, high value products including inhalation, long acting injectables, peptides and strategic 505(b)(2) brand products. Presently, Alvogen has over 30 products currently on market and extensive R&D capabilities fueling its growing pipeline. Alvogen maintains dedicated manufacturing facility in the United States, with significant capacity to expand. Alvogen是一傢俬營公司，專注於藥品的開發、許可、製造和營銷。Alvogen正在擴大其複雜的高價值產品組合，包括吸入劑、長效注射劑、肽和戰略性的505（b）（2）品牌產品。目前，Alvogen目前在市場上有30多種產品，廣泛的研發能力推動了其產品線的增長。Alvogen在美國設有專門的製造工廠，有很大的擴張能力。 About Lotus 關於蓮花 Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness. Lotus（1795：TT）成立於1966年，是一家國際製藥公司，業務遍及全球，專注於將新藥和仿製藥商業化，爲患者提供更好、更安全、更容易獲得的藥物。該公司擁有亞洲一流的研發和製造平台，已獲得包括美國食品藥品管理局、歐盟EMA、日本PMDA、中國食品藥品監督管理局和巴西ANVISA在內的全球主要監管機構的認證。Lotus 已在幾乎所有主要的全球市場建立了合作伙伴關係，包括美國、歐洲、日本、中國和巴西。該公司目前正在亞洲和美國開發和註冊超過100個經過戰略選擇的製藥項目，包括250多種商業產品。Lotus 通過內部研發投資和許可合作伙伴關係，投資多元化的投資組合，包括高屏障腫瘤學、複雜仿製藥、505 (b) 2、NCE 和生物仿製藥，以增強其投資組合的競爭力。 -- Sent from nPTT on my iPhone 13 mini -- ※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 111.250.199.2 (臺灣) ※ 文章網址: https://www.ptt.cc/bbs/Stock/M.1758658439.A.957.html